Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation

By  

Current Pharmaceutical Design, Vol. 16, Iss. 30, 2010-10 ,pp. : 3339-3351

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients

By  

Current Pharmaceutical Design, Vol. 16, Iss. 30, 2010-10 ,pp. : 3379-3389

Bentham Science Publishers

Access to resources Recommend Favorite

Cost-Efficacy Comparison among Three Antiretroviral Regimens in HIV-1 Infected, Treatment-Experienced Patients

By Ruof Jörg  

Clinical Drug Investigation, Vol. 27, Iss. 7, 2007-01 ,pp. : 469-479

Adis International

Access to resources Recommend Favorite

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients

By de Mendoza Carmen   Morelló Judit   Garcia-Gascó Pilar   Rodríguez-Novoa Sonia   Soriano Vincent  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 6, 2007-04 ,pp. : 839-850

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy

By Vidal Francesc   Domingo Pere   Viladés Consuelo   Peraire Joaquim   Arnedo Mireia   Alcamí José   Leal Manuel   Villarroya Francesc   Gatell Josep Ma  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1365-1382

Informa Healthcare

Access to resources Recommend Favorite